Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, mescaline, DMT +1 moreLSD, mescaline, DMT, other serotonergic hallucinogens show less
Psilocybin mushrooms
4-phosphoryloxy-N,N-dimethyltryptamine
Psilocybin mushrooms (Psilocybe spp., Hymenogastraceae) — magic mushrooms, shrooms — are psychoactive fungi comprising roughly 165 species found on every continent except Antarctica.[1] The dominant alkaloid, psilocybin, is converted by the body into psilocin, the compound responsible for the psychedelic state. Psilocin activates serotonin receptors in the cortex, disrupting the brain's default resting network and generating the characteristic psychedelic experience.[2]
Psilocybin mushrooms (Psilocybe spp., Hymenogastraceae) — magic mushrooms, shrooms — are psychoactive fungi comprising roughly 165 species distributed across every continent except Antarctica.[1] The dominant alkaloid, psilocybin, is a tryptamine prodrug dephosphorylated in the body to psilocin. Psilocin produces its principal effects by partially activating serotonin 5-HT₂A receptors on cortical neurons, disrupting default-mode network activity and generating the psychedelic state.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandLSD, mescaline, DMT +1 moreLSD, mescaline, DMT, other serotonergic hallucinogens show less
Ceremonial use in Mesoamerica dates to at least 1000 BCE; Albert Hofmann isolated psilocybin in 1958.[3] Prohibition under the 1971 UN Convention halted research for decades. Clinical trials in depression[4][5] and addiction[6] reignited scientific interest; Australia authorized therapeutic use in 2023, and Oregon and Colorado now operate regulated access frameworks.[7]
Subjective effects include brightened colors, geometric visual patterns, emotional enhancement, and — at higher doses — ego dissolution, where the sense of a separate self temporarily collapses.[8] The experience is shaped decisively by dose, psychological state, and environment; alkaloid content varies up to 11-fold within a single species.[9] Nausea during onset is common, and challenging experiences — panic, paranoia, thought loops — scale with dose.[10]
Psilocybin produces no physical dependence and no withdrawal;[11] acute physical toxicity at documented human doses is negligible.[12] The primary danger is psychological — difficult experiences at high doses — with lithium and MAOI co-administration posing the most serious drug interaction risks.[13] Wild-harvested specimens carry serious misidentification risk with lethal species such as Galerina marginata.[14]
History[edit]
Traditional and historical use
Archaeological evidence places ceremonial mushroom use in Mesoamerica at least as far back as 1000 BCE — stone effigies from highland Guatemala suggest organized ritual veneration.[15] The Aztecs called them teonanácatl ("flesh of the gods") and consumed them for healing, divination, and spiritual ceremony. R. Gordon Wasson attended a Mazatec velada in Oaxaca in 1955 and published his account in Life magazine in 1957, catalyzing Western interest while disrupting Mazatec communities.[16]
Research era and prohibition
Roger Heim described Psilocybe mexicana taxonomically in 1957, and Albert Hofmann at Sandoz isolated psilocybin and psilocin the following year.[3] Psychiatric research continued through the 1960s before psilocybin was placed in Schedule I under the US Controlled Substances Act in 1970 and the 1971 UN Convention.[7] The mushroom itself was not explicitly named in the 1971 convention — a legal ambiguity later exploited in several jurisdictions.[17]
Modern research revival
The Heffter Research Institute, founded in 1993, provided early infrastructure for renewed clinical work.[18] Griffiths and colleagues published a landmark 2006 study on psilocybin-occasioned mystical experiences,[8] followed by Phase 2 trials in treatment-resistant depression[4][5] and addiction.[6] Australia authorized therapeutic use in 2023; Oregon and Colorado established regulated access frameworks.[7] No Phase 3 trial is complete as of May 2026.
The Mazatec people of Oaxaca maintained continuous ceremonial mushroom use into the modern era through the velada — an all-night healing ceremony led by a curandera or curandero. Mushrooms were consumed as a sacrament within structured frameworks of preparation, intention, and community.[16] These practices represent documented historical and cultural tradition with specific therapeutic and spiritual parameters distinct from recreational consumption.
Botanical Overview[edit]
Taxonomy and classification
Psilocybe is a genus of small fungi in the family Hymenogastraceae, comprising roughly 165 recognized species.[1] The most widely cultivated species is Psilocybe cubensis, available in many named cultivars such as 'Golden Teacher' and 'Penis Envy'. P. semilanceata (the liberty cap) is the most common wild species in temperate Europe and North America.
Habitat and distribution
P. cubensis grows on bovine dung and enriched soils in tropical and subtropical regions. P. semilanceata inhabits acidic, sheep-grazed grasslands across the British Isles, Scandinavia, and the Pacific Northwest. P. cyanescens (wavy cap) colonizes wood-chip mulch in urban and suburban gardens.
Identification
Psilocybin-containing species share several field features: small fruiting bodies, a cap that shifts color as moisture changes (hygrophanous), dark purple-brown spore prints, and blue bruising where tissue is damaged. Galerina marginata — a lethal species — grows on the same wood-chip substrates as P. cyanescens and can look similar to inexperienced foragers.[14] Spore print color is the key distinction: Galerina prints rusty brown; Psilocybe prints dark purple-brown.
Alkaloid Profile[edit]
Dominant alkaloid: psilocybin and psilocin
Psilocybin is the dominant alkaloid in Psilocybe mushrooms, functioning as a prodrug. The body converts it to psilocin — the compound that produces psychedelic effects by activating serotonin receptors in the cortex.[19] In dried P. cubensis, psilocybin content typically ranges from about 0.14% to 1.86% by dry weight.[20]
Minor alkaloids
Several minor alkaloids co-occur with psilocybin in most Psilocybe species. Baeocystin, norbaeocystin, and aeruginascin have been identified across various strains — aeruginascin has been linked anecdotally to differences in subjective character in some P. cubensis strains. No controlled human studies have isolated the contributions of any minor alkaloid; their role in shaping the experience remains unresolved.
Variability
Alkaloid concentrations vary dramatically across species, cultivars, and individual specimens — up to 11-fold within a single P. cubensis population.[9] Named cultivar reputations (e.g., 'Penis Envy' for high potency) carry some weight among cultivators, but standardized analytical data remain limited.[20] This variability is the central challenge for consistent dosing with whole-mushroom preparations.
Neuroscience[edit]
Where it acts
Psilocin binds primarily to serotonin receptors on cortical neurons.[19][21] Brain imaging confirms that the intensity of the psychedelic experience correlates directly with how much of those receptors psilocin occupies.[2] The disruption of the brain's default resting network — the circuit active during self-referential thought — produces ego dissolution and the characteristic sense of boundary loss.
What it changes
A 2024 study showed that a single 25 mg psilocybin dose produces massive desynchronization across brain networks — connectivity changes more than three times those from methylphenidate.[22] Psilocybin also promotes the growth of new neural connections,[23] and these connectivity changes can persist for weeks, linked to antidepressant effects.[22] Tolerance builds within 24 hours through serotonin downregulation[21] and resets fully after approximately 7 days.
- Whether tea, lemon-acidified, or edible preparations produce meaningfully different psilocin exposure profiles remains uncharacterized in published studies.
- The functional contributions of minor alkaloids (baeocystin, norbaeocystin, aeruginascin) to the subjective experience have not been studied in controlled human trials.
- Whether CYP2D6 genetic variation should inform clinical dosing decisions has not been prospectively investigated.
Subjective Effects[edit]
The psilocybin mushroom experience unfolds in layers. At lower doses, colors intensify, surfaces appear to breathe with subtle movement, and mood lifts into an open, wondering state.[8] As dose increases, effects deepen into vivid visual phenomena, emotional catharsis, and — at the upper range — ego dissolution, where the boundary between self and environment collapses. Set and setting exert outsized influence; the same dose can produce radically different outcomes depending on mental state and environment.[24]
Among serotonergic psychedelics, psilocybin mushrooms occupy a middle position. The experience is shorter than LSD (4–8 hours versus 8–12) and more prolonged and perceptually elaborate than vaporized DMT. Tea preparations produce faster onset and shorter total duration than dried whole fruiting bodies. The pronounced nausea of whole dried mushrooms distinguishes them from the synthetic psilocybin capsules used in clinical settings.
Ceremonial use in Mesoamerica dates to at least 1000 BCE; Hofmann isolated psilocybin in 1958.[3] Prohibition under the 1971 UN Convention halted research for decades until landmark trials in depression[4][5] and substance use disorders[6] reignited scientific interest. Australia authorized therapeutic use in 2023; Oregon and Colorado operate regulated access frameworks; no Phase 3 data exist as of May 2026.[7]
Subjective effects include perceptual intensification, geometric visual phenomena, emotional enhancement, cognitive flexibility, and ego dissolution at higher doses.[8] The experience is shaped decisively by preparation method, specimen potency, and psychological set and setting; alkaloid content varies up to 11-fold within a single species.[9] Nausea is common with whole fruiting bodies, and challenging psychological experiences scale with dose.[10]
Psilocybin produces no physical dependence; tolerance develops rapidly and resets in approximately 7 days, making daily use self-limiting.[11] The primary risk is psychological — challenging experiences at higher doses — with lithium or MAOI co-administration constituting dangerous interactions.[12] Acute physical toxicity is negligible at documented human doses,[13] though wild-harvested specimens carry misidentification risk with lethal species such as Galerina marginata.[14]
History[edit]
Traditional and historical use
Archaeological evidence of psilocybin mushroom use in Mesoamerica extends to at least 1000 BCE. Stone mushroom effigies from highland Guatemala, dated between roughly 1000 BCE and 900 CE, suggest organized ritual veneration of fungi — a practice sometimes termed mycolatry.[15] Aztec sources refer to the mushrooms as teonanácatl ("flesh of the gods"), describing ceremonial consumption for healing, divination, and spiritual communion.
Western discovery
R. Gordon Wasson, an amateur mycologist, participated in a Mazatec velada led by curandera María Sabina in Oaxaca, Mexico in 1955. His account, published in Life magazine in May 1957, introduced the term "magic mushroom" — a phrase added by an editor without Wasson's consent — and catalyzed Western interest while ultimately disrupting Mazatec communities.[16] Roger Heim provided the formal taxonomic description of Psilocybe mexicana in 1957, and Albert Hofmann at Sandoz Laboratories isolated psilocybin and psilocin the following year.[3]
Research era and prohibition
Psychiatric research with psilocybin proceeded through the 1960s at Harvard and other institutions before being curtailed when psilocybin and psilocin were placed in Schedule I under the US Controlled Substances Act in 1970, and subsequently under the 1971 UN Convention on Psychotropic Substances.[7] The physical mushroom was not explicitly named in the 1971 convention — a legal ambiguity later exploited in several jurisdictions.[17]
Modern research revival
The Heffter Research Institute, founded in 1993, provided early infrastructure for renewed clinical work.[18] Griffiths and colleagues published the pivotal 2006 study demonstrating that psilocybin could occasion mystical-type experiences with sustained personal meaning.[8] Subsequent milestones include the COMPASS COMP360 Phase 2 trial for treatment-resistant depression,[4] a single-dose MDD trial published in JAMA,[5] Oregon's regulated therapeutic framework (operational 2023), Australia's authorization of therapeutic psilocybin (2023), and a US executive order in April 2026 directing fast-tracked psychedelic research review.[7] No Phase 3 randomized controlled trial has been completed as of May 2026.
The Mazatec people of Oaxaca maintained continuous ceremonial mushroom use into the modern era through the velada — an all-night healing ceremony led by a curandera or curandero. Mushrooms were consumed as a sacrament within structured frameworks of preparation, intention, and community.[16] These practices represent documented historical and cultural tradition with specific therapeutic and spiritual parameters distinct from recreational consumption.
Botanical Overview[edit]
Taxonomy and classification
Psilocybe is a genus of small, spore-bearing fungi in the family Hymenogastraceae. Approximately 165 species are recognized, distributed across all continents except Antarctica.[1] The most commonly encountered species in cultivation and commerce is Psilocybe cubensis, a pantropical fungus with numerous named cultivars (e.g., "Golden Teacher," "B+," "Penis Envy"). Psilocybe semilanceata (liberty cap) is the most widespread wild species in temperate Europe and North America.
Habitat and distribution
Psilocybe species occupy diverse ecological niches. P. cubensis fruits on bovine dung and enriched soils in tropical and subtropical regions. P. semilanceata grows in acidic grasslands, particularly sheep-grazed pastures in the British Isles, Scandinavia, and the Pacific Northwest. P. cyanescens (wavy cap) colonizes wood-chip mulch in urban and suburban settings. Wild populations of many species remain poorly surveyed outside North America and Western Europe.
Identification
Psilocybin-containing species share several macroscopic features: small to medium fruiting bodies, a hygrophanous cap (color shifts as moisture content changes), dark purple-brown spore prints, and — critically — blue bruising of damaged tissue, caused by oxidative polymerization of psilocin. Blue bruising is the most reliable field indicator of psilocybin content, though it is not unique to Psilocybe and may be absent in some low-potency species.
Misidentification is the most serious safety concern for wild foragers. Galerina marginata, a lethal amatoxin-containing species, co-occurs with P. cyanescens on wood-chip substrates and can appear similar to inexperienced collectors.[14] Spore print color (Galerina: rusty brown; Psilocybe: dark purple-brown) is the primary distinguishing feature.
Harvesting and processing
Cultivated P. cubensis is typically harvested just before or as the veil separating cap from stem tears, then dried at low heat to preserve alkaloid content. Wild-harvested specimens require expert identification before consumption. Fruiting bodies are consumed dried, brewed as tea, or incorporated into edible preparations. Potency varies substantially: alkaloid content can differ up to 11-fold between individual specimens within a single species.[9]
Alkaloid Profile[edit]
Dominant alkaloid: psilocybin and psilocin
psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the dominant alkaloid in Psilocybe mushrooms, functioning as a prodrug. After ingestion, alkaline phosphatases in the gut, liver, and blood cleave its phosphate group to yield psilocin (4-hydroxy-N,N-dimethyltryptamine) — the compound responsible for psychoactive effects. Psilocin acts as a partial agonist at serotonin 5-HT₂A receptors, the receptor interaction that drives the psychedelic experience.[19] Psilocybin content in P. cubensis dried fruiting bodies typically ranges from approximately 0.14% to 1.86% by dry weight, though peer-reviewed HPLC data for individual cultivars remain sparse.[20]
Minor alkaloids
Several minor tryptamine alkaloids co-occur with psilocybin in most Psilocybe species. Baeocystin (4-phosphoryloxy-N-methyltryptamine), the nor-methyl structural analog of psilocybin, is the most commonly reported minor constituent. Norbaeocystin (4-phosphoryloxy-tryptamine) is present at lower concentrations. Aeruginascin (trimethyl-4-phosphoryloxytryptamine) has been identified in some species, particularly P. cubensis strains anecdotally associated with experiential differences. No controlled human studies isolating the contributions of any minor alkaloid exist; their functional role in modulating the subjective experience is unresolved.
Variability
Alkaloid concentrations vary dramatically across species, cultivars, individual specimens, and even different regions of the same fruiting body. Within a single P. cubensis population, total psilocybin content can vary up to 11-fold.[9] Growing conditions — substrate composition, temperature, humidity, and light exposure — influence alkaloid production. Named cultivar designations (e.g., "Penis Envy," "Albino A+") carry characteristic potency reputations among cultivators, but standardized analytical data are limited.[20] This variability is the single largest unresolved challenge for consistent dosing with whole-mushroom preparations.
Pharmacokinetics summary
Psilocybin is converted to psilocin primarily by alkaline phosphatases before and during first-pass metabolism. Oral bioavailability of psilocin is approximately 52.7 ± 20%, with peak plasma concentrations reached at 1.8–4 hours and an half-life of 1.5–4 hours.[21] Psilocin is metabolized principally via CYP2D6 and CYP3A4, with secondary metabolism by MAO-A.[21] CYP2D6 poor metabolizers (approximately 5–10% of Caucasian populations) may experience prolonged psilocin exposure.[21] Route-specific pharmacokinetics for tea preparations and other non-capsule oral forms have not been characterized in published studies.
Neuroscience[edit]
Where it acts
Psilocin binds primarily to 5-HT₂A receptors on cortical pyramidal neurons in layers V and VI.[19][22] PET imaging confirms that subjective psychedelic intensity correlates directly with 5-HT₂A receptor occupancy,[2] and the selective antagonist ketanserin abolishes psilocybin's perceptual effects. Secondary activity at 5-HT₁A receptors may contribute an anxiolytic modulating tone.[22] For detailed receptor binding data, see Psilocin.
What it changes
5-HT₂A activation triggers a cascade of glutamate release in cortical circuits. A 2024 Nature study demonstrated that a single 25 mg psilocybin dose produces massive desynchronization of brain connectivity — a broadband power reduction across posterior cortices and the default mode network (DMN), with connectivity changes exceeding three times those produced by methylphenidate.[23] Psilocybin also promotes synaptogenesis and dendritic spine remodeling via BDNF upregulation through 5-HT₂A-mediated signaling.[24] Persistent reductions in hippocampal-to-DMN connectivity lasting weeks after administration have been linked to therapeutic response in depression.[23]
Two theoretical models dominate. The entropic brain hypothesis proposes that psilocybin elevates entropy in brain connectivity, pushing toward higher criticality with richer repertoires of functional states.[25] The REBUS model integrates predictive processing: psilocybin relaxes rigid high-level prior beliefs, increasing sensitivity to bottom-up sensory input — a mechanism proposed to explain revision of entrenched depressive thought patterns.[26]
- Whether tea, lemon-acidified, or edible preparations produce meaningfully different psilocin exposure profiles remains uncharacterized in published studies.
- The functional contributions of minor alkaloids (baeocystin, norbaeocystin, aeruginascin) to the subjective experience have not been studied in controlled human trials.
- Whether CYP2D6 genetic variation should inform clinical dosing decisions has not been prospectively investigated.
Subjective Effects[edit]
The psilocybin mushroom experience unfolds as a unified arc of perceptual, emotional, and cognitive transformation. At lower doses, colors brighten, surfaces breathe with subtle geometric patterning, and mood lifts into gentle wonder. As dose increases, these effects deepen into vivid visual hallucinations, profound emotional catharsis, and — at the upper range — ego dissolution, where the boundary between self and environment temporarily collapses.[8] Set and setting exert outsized influence: the same dose in the same person can produce radically different outcomes depending on psychological preparation and environment.[27]
Among serotonergic psychedelics, psilocybin mushrooms sit in a middle position — shorter and generally more manageable than LSD (8–12 hours), longer and more perceptually elaborate than vaporized DMT. Tea preparations produce faster onset and shorter total duration than whole dried fruiting bodies. The pronounced body load — particularly nausea — distinguishes mushroom preparations from synthetic psilocybin capsules used in clinical settings.
Effect Grid
A full psychedelic experience. Geometry — structured visual patterns, lattices, and mandalas — becomes prominent with eyes open or closed. Color alteration transforms the visual field; depth perception distortion and visual morphing reshape spatial relationships. Internal hallucinations develop as vivid closed-eye imagery. Environmental patterning overlays surfaces with repeating motifs.
Emotional enhancement intensifies significantly in both positive and challenging directions. Thought connectivity links disparate concepts; pattern recognition enhancement and conceptual thinking produce novel associations. Personal insight and introspection enhancement deepen. Ego boundaries begin to soften, introducing early identity alteration. Confusion and thought loops may emerge intermittently. Time alteration is pronounced — minutes feel stretched.
Nausea is common at onset, particularly with whole dried mushroom material (less with tea). Pupil dilation is marked. Bodily heaviness or body schema distortion may occur. Motor control impairment makes navigation clumsy. Functional capacity is substantially reduced — plan for 4–6 hours of commitment with dried fruiting bodies. Drug dose is the single most important predictor of all acute response variables (Studerus 2012).
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory enhancement · Geometry · Visual breathing · Tracers · After-images · Symmetrical texture repetition · Perspective distortion · Depth perception distortion · Brightness alteration · Environmental patterning · Visual morphing · Touch enhancement · Visual haze / noise · Visual diffraction · Auditory distortion · Sound sensitivity · Visual melting · Peripheral vision distortion · Spatial disorientation · Vestibular distortion · Synesthesia · Light sensitivity · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Visual acuity enhancement · Dreaming enhancement · Visual magnification · Taste enhancement · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Flashbacks · Environmental orbism / cubism · Object activation · Visual scenery slicing · Perspective hallucinations · Auditory hallucinations · Olfactory hallucination · Persisting hallucinations
After-images · Symmetrical texture repetition · Perspective distortion · Depth perception distortion · Brightness alteration · Environmental patterning · Visual morphing · Touch enhancement · Visual haze / noise · Visual diffraction · Auditory distortion · Sound sensitivity · Visual melting · Peripheral vision distortion · Spatial disorientation · Vestibular distortion · Synesthesia · Light sensitivity · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Visual acuity enhancement · Dreaming enhancement · Visual magnification · Taste enhancement · Internal hallucinations · Visual recursion · Object transformations · External hallucinations · Flashbacks · Environmental orbism / cubism · Object activation · Visual scenery slicing · Perspective hallucinations · Auditory hallucinations · Olfactory hallucination · Persisting hallucinations
Body high · Spontaneous body sensations · Body schema distortion · Stimulation · Appetite suppression · Laughter fits · Physical fatigue · Tingling / electric sensations · Bodily heaviness · Muscle tension · Bodily lightness · Tactile euphoria · Vibrations / buzzing · Breathing alteration · Dizziness · Excessive sweating · Heart rate perception changes · Insomnia · Wakefulness · Sedation · Pain suppression · Bodily pressures · Dry mouth · Muscle relaxation · Restlessness · Headache · Trembling · Watery eyes · Nasal congestion · Salivation · Involuntary body movements · Diarrhea · Nystagmus (eye wobbles) · Vomiting · Yawning · Increased urination · Brain zaps · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Stimulation · Appetite suppression · Laughter fits · Physical fatigue · Tingling / electric sensations · Bodily heaviness · Muscle tension · Bodily lightness · Tactile euphoria · Vibrations / buzzing · Breathing alteration · Dizziness · Excessive sweating · Heart rate perception changes · Insomnia · Wakefulness · Sedation · Pain suppression · Bodily pressures · Dry mouth · Muscle relaxation · Restlessness · Headache · Trembling · Watery eyes · Nasal congestion · Salivation · Involuntary body movements · Diarrhea · Nystagmus (eye wobbles) · Vomiting · Yawning · Increased urination · Brain zaps · Bodily dissociation · Tactile hallucination
Introspection enhancement · Openness enhancement · Cognitive flexibility · Pattern recognition enhancement · Conceptual thinking · Novelty enhancement · Increased nature relatedness · Cognitive euphoria · Confusion · Memory suppression · Focus suppression · Multiple thought streams · Cognitive impairment · Creativity enhancement · Humor enhancement · Language suppression · Thought deceleration · Thought loops · Cognitive fatigue · Memory fragmentation · Memory replays · Motivation suppression · Synchronicity · Analysis suppression · Information processing suppression · Thought disorganization · Analysis enhancement · Thought organization · Information processing enhancement · Thought acceleration · Cognitive dysphoria · Memory enhancement · Focus enhancement · Delusions · Delirium
Pattern recognition enhancement · Conceptual thinking · Novelty enhancement · Increased nature relatedness · Cognitive euphoria · Confusion · Memory suppression · Focus suppression · Multiple thought streams · Cognitive impairment · Creativity enhancement · Humor enhancement · Language suppression · Thought deceleration · Thought loops · Cognitive fatigue · Memory fragmentation · Memory replays · Motivation suppression · Synchronicity · Analysis suppression · Information processing suppression · Thought disorganization · Analysis enhancement · Thought organization · Information processing enhancement · Thought acceleration · Cognitive dysphoria · Memory enhancement · Focus enhancement · Delirium
Emotional lability · Catharsis · Simultaneous emotions · Anxiety suppression · Anxiety · Dysphoria
Anxiety · Dysphoria
Communication suppression · Depersonalization · Disinhibition · Sociability enhancement · Compulsive behavior reduction · Sociability suppression · Communication enhancement · Flow state · Social disconnection · Ego inflation · Boundary dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings · Ego dissolution
Compulsive behavior reduction · Sociability suppression · Communication enhancement · Flow state · Social disconnection · Ego inflation · Boundary dissolution · Identity alteration · Cognitive disconnection · Telepathic feelings · Ego dissolution
Time cessation
Entity contact · Transpersonal visions · Cessation · Transpersonal memory access · Voidness · Death-rebirth sequence · Near-death experience
Voidness · Death-rebirth sequence · Near-death experience
Recursive awareness
Timeline · by preparation
Preparations[edit]
Psilocybin mushrooms are consumed in several distinct preparations, each with different onset, duration, and intensity. Potency varies up to 11-fold between individual specimens within the same species,[9] making preparation-specific dosing essential.
Dried Fruiting Bodies
The most common preparation worldwide. Whole mushrooms are dried at low heat and consumed directly, ground into capsules, or mixed into food.
- Dose (dried whole): Threshold: 0.1–0.25 g. Common: 1–2.5 g. Strong: 2.5–5 g.
- Onset: 30–60 minutes.
- Duration: 4–8 hours.
- Nausea during onset is common, caused by indigestible fungal cell wall material.
Tea Infusion
Crushed dried mushrooms steeped in hot (not boiling) water for 10–20 minutes, often with ginger or lemon juice.
- Dose (tea): Same starting weight as dried fruiting bodies.
- Onset: 15–30 minutes (faster than whole dried material).
- Duration: 3–5 hours.
- Route-specific pharmacokinetic data for tea have not been published in peer-reviewed studies.
Lemon Tek
Ground dried mushrooms soaked in lemon or lime juice for 15–30 minutes before ingestion. The acidic environment is proposed to accelerate conversion of psilocybin to psilocin before consumption.
- Dose (lemon tek): Treat as more potent per gram than equivalent dried material consumed directly.
- Onset: 15–20 minutes.
- Duration: 3–4 hours, with a more compressed and intense peak.
- This mechanism has not been confirmed in published pharmacokinetic studies.
Edible Preparations (Chocolates, Gummies)
Ground mushroom material incorporated into food products. Increasingly common in unregulated markets.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DMT
Toxicity
No lethal dose has been established for psilocybin.[12] Clinical data across 598 participants showed nausea, headache, and transient anxiety as the most common adverse events — no serious adverse events were attributable to psilocybin.[26] A 2023 clinical trial found higher overall adverse event rates at 25 mg versus placebo, but no serious treatment-emergent events.[5]
Transient blood pressure and heart rate increases occur during the acute experience. A case series of Psilocybe keralensis poisonings documented myocardial injury with cardiovascular complications — findings not replicated with P. cubensis or other commonly consumed species.[27]
Commercial edibles carry the highest adulteration risk, with inconsistent formulations and unlisted ingredients documented in NPDS data.[25] Wild-harvested specimens risk misidentification with lethal species (see Botanical Overview). Ehrlich reagent (purple/violet reaction) confirms indole tryptamine presence but cannot determine dose.
Psychological Risks
Challenging experiences are common at higher doses — particularly with negative mindset or unsupportive setting. Dose is the single most important predictor of acute response.[24] In a US survey, 8.9% of lifetime psychedelic users reported impairment lasting more than a day from their most difficult experience, and 2.6% sought medical or psychiatric help.[10]
Psilocybin is contraindicated in people with personal or family history of psychotic spectrum disorders — clinical trials uniformly exclude these populations,[17][5] as psilocybin may trigger or worsen psychotic episodes in vulnerable individuals.[17]safety citation needed Persistent perceptual disturbances (HPPD) are rare but documented.[28][29]
Tolerance & Dependence
Tolerance builds virtually completely within 24 hours via serotonin downregulation[21] and resets fully after approximately 7 days. Cross-tolerance occurs with LSD and other serotonergic hallucinogens but not with non-serotonergic substances.[19]
Psilocybin produces no physical dependence and no withdrawal.[11][6] Psychological dependence liability is very low — no compulsive use patterns comparable to classical drugs of abuse have been documented.[25] The rapid tolerance mechanism makes daily use pharmacologically self-limiting.
Drug Interactions
Lithium — dangerous. Co-use with lithium is the strongest predictor of serious harm from psilocybin in population data.[10] Lithium lowers the seizure threshold; combined with serotonergic stimulation, this creates seizure risk.safety citation needed
MAOIs — dangerous. MAOIs block psilocin breakdown and simultaneously raise serotonin levels, creating risk of hypertensive emergency.[13]
Tramadol — dangerous (pharmacological plausibility). Tramadol's serotonergic activity creates theoretical serotonin syndrome risk in combination with psilocybin.safety citation needed No peer-reviewed case reports of this specific combination have been identified.
Cannabis — unknown. One case of persistent perceptual disturbance followed combined psilocybin and cannabis use.[28] Cannabis may amplify subjective intensity; no controlled interaction studies exist.
SSRIs. Chronic SSRI use generally blunts psilocybin's effects through serotonin receptor downregulation.[30] The combination does not appear dangerous at standard doses but significantly reduces therapeutic efficacy.
Contraindications
Psychotic spectrum disorders (schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features) — personal or family history. All clinical trials exclude these populations.[17][5] Absolute contraindication.
Active suicidal ideation with intent or plan — emotional enhancement during a high-dose experience creates unacceptable risk. Absolute contraindication.
Lithium or MAOI co-administration — dangerous interactions documented above. Absolute contraindication.
Cardiovascular disease — transient hypertension and tachycardia warrant caution; a myocardial injury case series raises additional concern.[27] Relative contraindication.
Pregnancy — no peer-reviewed human safety data exist.safety citation needed Relative contraindication.
Pediatric use — no clinical safety data in individuals under 18. Contraindicated.
Harm Reduction[edit]
Forms & Identification
Lab testing is the only reliable way to confirm psilocybin content and rule out adulterants. For whole dried mushrooms, visual identification by an experienced mycologist combined with spore-print verification provides reasonable species confidence. Commercial edibles cannot be visually assessed for content or purity — analytical testing is the only safeguard against inconsistent dosing and synthetic adulterants.[25]
Ehrlich reagent provides a basic screen: a purple/violet reaction confirms an indole tryptamine is present but cannot identify the compound or determine dose. When lab testing is unavailable, starting with a fraction of a typical dose is the most practical harm-reduction strategy.
Guidelines
Practical Guidelines
- 1. Test first. Use Ehrlich reagent at minimum. Purple/violet confirms indole presence. No reaction: do not consume.
- 2. Start low. For unfamiliar specimens or cultivars, begin with 0.5–1 g dried and assess potency before taking more. Specimen-to-specimen variability is substantial.[9]
- 3. Wait before redosing. Onset from dried mushroom material is 30–60 minutes. Do not redose during this window. Tea and lemon tek onset faster (15–30 minutes).
- 4. Prepare the environment. Choose a comfortable indoor space with soft lighting, access to water, calming music, and a sober companion.
- 5. Allow enough time. The experience lasts 6–8 hours — do not drive, operate machinery, or make consequential decisions until fully baseline.
- 6. Hydrate and eat lightly. A light meal 2–3 hours before consumption reduces nausea. Keep water accessible throughout.
- 7. Avoid dangerous combinations. Do not combine with lithium, MAOIs, or tramadol.[13]
Set & Setting
Psilocybin's effects are unusually sensitive to psychological state and physical environment. A calm, familiar, physically safe space with minimal external stimulation reduces the likelihood of a challenging experience. Avoid public settings, crowds, or situations requiring coordination or rapid decision-making.
Unresolved anxiety, acute grief, or emotional distress raises the risk of difficult experiences.[24] A trusted, sober companion who can provide calm reassurance is strongly recommended, especially at higher doses or for first experiences.
Aftercare & integration. The period following a psilocybin experience often carries emotional residue — positive or challenging — that benefits from deliberate processing. Rest, adequate sleep, and good nutrition in the 24–48 hours afterward support recovery.
Journaling or conversation with a trusted person helps consolidate insights and process difficult material. For experiences that included challenging psychological content, integration work is particularly important: unprocessed difficult experiences can manifest as lingering anxiety or confusion.
Mild headache is common in the hours afterward. Hydration and over-the-counter analgesics are typically sufficient. If persistent mood disturbance, depersonalization, or perceptual changes continue beyond a few days, consult a mental health professional.
Recovery & Support
Psilocybin carries very low abuse liability, and most users do not develop problematic patterns. However, some individuals experience psychological difficulty integrating intense psychedelic experiences, or develop habitual use that interferes with daily functioning.
For persistent psychological difficulties after psychedelic use — including anxiety, depersonalization, or existential distress — specialized integration therapy is available through directories such as the Psychedelic Support Network and MAPS therapist finder.
Tolerance resets fully in approximately 7 days. Spacing sessions at least 1–2 weeks apart preserves sensitivity and reduces risk of psychological overload.
For crisis support, contact the Fireside Project psychedelic peer support line (62-FIRESIDE / 623-473-7433) or the SAMHSA National Helpline (1-800-662-4357), available 24/7.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe panic or paranoia unresponsive to reassurance
- Dissociation so profound the person cannot communicate or recognize surroundings
- Seizure activity (especially if lithium has been co-administered)
- Signs of serotonin syndrome: hyperthermia, rigid muscles, rapid heart rate, agitation
- Chest pain or difficulty breathing
Immediate steps:
- 1. Stay with the person. Move to a quiet, safe space if possible.
- 2. Speak calmly and reassuringly. Remind them the effects are temporary and will pass.
- 3. If severely distressed and unresponsive to reassurance, call emergency services.
- 4. If seizures occur, protect the head and call emergency services immediately.
What to tell the dispatcher:
- The substance consumed (psilocybin mushrooms), approximate amount, and time of ingestion
- Current symptoms
- Any co-administered substances, particularly lithium or MAOIs
- Good Samaritan laws provide legal protection in many jurisdictions
Reversal agents: No specific pharmacological reversal agent exists for psilocybin. Benzodiazepines may be administered by medical professionals for severe anxiety or agitation.
Legal Status[edit]
Psilocybin and psilocin are listed under Schedule I of the 1971 UN Convention on Psychotropic Substances. The physical mushroom was not explicitly named in the Convention — a legal ambiguity exploited in several jurisdictions.[17] In the United States, psilocybin remains federally Schedule I; an April 2026 executive order directed fast-tracked psychedelic research review but did not alter scheduling.[7] Oregon and Colorado have established regulated access frameworks; several US cities, including Denver, Oakland, and Seattle, have enacted decriminalization ordinances. Australia became the first country to authorize therapeutic psilocybin use in 2023, under licensed psychiatrist supervision. Canada's Special Access Program permits access for serious conditions. The United Kingdom classifies psilocybin as Class A. The Netherlands prohibits fruiting bodies but permits psilocybin-containing truffles in licensed shops. Germany has opened compassionate access at two clinics, and the Czech Republic became the first EU member state with a specific medical psilocybin framework in January 2026.[7] Possession remains a serious criminal offense in most jurisdictions worldwide.
Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · mesc · DMT
Toxicity
No human lethal dose has been established for psilocybin; a systematic toxicology review concluded that no dose has been identified above which psilocybin endangers life.[13] Clinical trial data across 598 participants identified nausea, headache, and transient anxiety as the most common adverse events, with no serious adverse events attributable to psilocybin.[28] The Raison et al. 2023 JAMA trial found higher overall adverse event rates with 25 mg psilocybin versus placebo, consistent with mild physiological burden, but no serious treatment-emergent events.[5]
Transient increases in blood pressure and heart rate occur during the acute psychedelic state. A case series of Psilocybe keralensis poisonings documented myocardial injury with cardiovascular complications — findings not replicated with P. cubensis or other commonly consumed species.[29]
Contaminant and adulterant risk is preparation-dependent. Wild-harvested specimens carry misidentification risk with lethal species (see Botanical Overview) and potential pesticide or herbicide exposure from treated soils. Cultivated P. cubensis carries lower contamination risk under sterile conditions, though mold growth on inadequately dried material poses a mycotoxin concern.
Commercial edibles (chocolates, gummies) present the most significant adulteration risk: NPDS 2023–2024 data document unregulated products with unlisted ingredients and inconsistent formulations.[30] Synthetic adulterants — particularly NBOMe-class compounds misrepresented as psilocybin — have been documented in the broader psychedelics market, primarily in pressed tablets and blotter. Whole dried mushrooms are less susceptible to synthetic adulteration than processed preparations.
Ehrlich reagent testing turns purple/violet in the presence of indole tryptamines including psilocybin and psilocin, providing a basic screening method. Ehrlich testing cannot confirm dose or distinguish between tryptamine compounds. No ISO/IEC-accredited laboratory testing framework exists for psilocybin mushroom products outside Australia's regulated therapeutic context.
Psychological Risks
Challenging experiences ("bad trips") are common at higher doses, particularly with negative mindset, insufficient preparation, or unsupportive setting. Drug dose is the single most important predictor of all acute response variables.[27]
In a nationally representative US adult sample, 8.9% of lifetime psychedelic users reported functional impairment lasting more than one day from their most challenging experience, and 2.6% sought medical or psychiatric assistance.[10] Features include anxiety, panic, paranoia, thought loops, and ego dissolution experienced as frightening. These events generally resolve as drug effects wane.
Psilocybin is contraindicated in individuals with personal or family history of psychotic spectrum disorders. Clinical trials uniformly exclude these populations.[17][5] Psilocybin may precipitate or exacerbate psychotic episodes in vulnerable individuals.[17] safety citation needed
Hallucinogen persisting perception disorder (HPPD) is rare but documented. At least one case report describes HPPD persisting more than 8 months following combined psilocybin and cannabis use.[31] Controlled data attribute flashback phenomena less strongly to psilocybin than to LSD.[32]
Extended difficulties — including anxiety, existential struggle, social disconnection, and depersonalization — affect a subset of users. For approximately one-third of those reporting extended difficulties, problems persisted more than one year. Guided settings are associated with a narrower range of difficulties than unguided use.citation needed
Tolerance & Dependence
Tolerance develops virtually completely within 24 hours via 5-HT₂A downregulation.[22] Cross-tolerance is complete with LSD and other serotonergic hallucinogens but does not extend to non-serotonergic substances.[19] Full reset requires approximately 7 days.
Psilocybin produces no physical dependence or withdrawal.[11][6] Psychological dependence liability is very low; no compulsive use patterns comparable to classical drugs of abuse have been documented.[30] The rapid tolerance mechanism makes daily use pharmacologically self-limiting.
Drug Interactions
Lithium and mood stabilizers — dangerous. Co-use of lithium with psilocybin is the strongest predictor of challenging experiences and overall harm in population data.[10] The proposed mechanism involves lithium's seizure-threshold-lowering effect combined with serotonergic stimulation. safety citation needed
MAOIs — dangerous. Co-administration is associated with hypertensive urgency or emergency.[12] MAO-A inhibition increases psilocin exposure while simultaneously elevating serotonin levels, creating both pharmacokinetic and pharmacodynamic amplification.
Tramadol — dangerous (pharmacological plausibility). Tramadol's serotonergic activity creates theoretical serotonin syndrome risk when combined with psilocybin. safety citation needed No peer-reviewed case reports of this specific combination have been identified.
Cannabis — unknown. One HPPD case followed combined psilocybin and cannabis use.[31] Cannabis may amplify subjective intensity, but no controlled interaction studies exist.
SSRIs. Chronic SSRI use generally blunts psilocybin's effects through 5-HT₂A downregulation. A Phase 2 exploratory study of concurrent SSRI use found mild adverse events only and no serious events.[33] The combination does not appear dangerous at standard SSRI doses but significantly reduces therapeutic efficacy.
CYP-mediated interactions. Psilocin is metabolized by CYP2D6 and CYP3A4.[21] Strong inhibitors of these enzymes (e.g., fluoxetine, paroxetine, ketoconazole, ritonavir) could prolong psilocin exposure. CYP3A4 inducers (e.g., carbamazepine, rifampin) could reduce it. These interactions have not been systematically characterized in clinical studies.
Contraindications
Psychotic spectrum disorders — personal or family history of schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features. All clinical trials exclude these populations.[17][5] Absolute contraindication.
Active suicidal ideation with intent or plan — uncontrolled emotional enhancement during a high-dose experience creates unacceptable risk. Absolute contraindication.
Lithium or MAOI co-administration — dangerous interactions documented above. Absolute contraindication.
Cardiovascular disease — transient hypertension and tachycardia warrant caution; the P. keralensis myocardial injury case series raises additional concern.[29] Relative contraindication.
Pregnancy — no peer-reviewed human safety data exist. safety citation needed Relative contraindication.
Pediatric use — no clinical safety data in individuals under 18. Contraindicated.
Preparations[edit]
Dried fruiting bodies
Dried fruiting bodies are the most common preparation worldwide. Whole mushrooms are dried at low heat and consumed directly, ground into capsules, or mixed into food. Potency varies substantially by species and individual specimen; alkaloid content can differ up to 11-fold within P. cubensis alone.[9] Threshold doses begin around 0.1–0.25 g dried; a common dose is 1–2.5 g; strong experiences typically require 2.5–5 g. Onset is 30–60 minutes, peak effects at 1.5–2.5 hours, and total duration 4–8 hours. Nausea during the come-up is common, attributed to indigestible fungal cell wall material.
Tea infusion
Tea is prepared by steeping crushed or ground dried mushrooms in hot (not boiling) water for 10–20 minutes, often with ginger or lemon juice. Tea preparations are widely reported to produce faster onset (15–30 minutes), reduced nausea, and shorter total duration (3–5 hours) compared to whole dried material. Route-specific pharmacokinetic data for tea have not been published in peer-reviewed studies. Dose ranges are equivalent to dried fruiting bodies by weight of starting material.
Lemon tek
Lemon tek involves soaking ground mushrooms in lemon or lime juice for 15–30 minutes before ingestion. The acidic environment is proposed to accelerate dephosphorylation of psilocybin to psilocin before consumption, compressing onset to 15–20 minutes and intensifying peak effects while shortening total duration to 3–4 hours. This mechanism has not been confirmed in published pharmacokinetic studies. Users should treat lemon tek preparations as more potent per gram than equivalent dried material consumed directly.
Edible preparations (chocolates, gummies)
Chocolate bars and gummies containing ground mushroom material or crude extracts are increasingly common in unregulated markets. Dosing accuracy varies widely; NPDS data document inconsistent formulations and unlisted ingredients in these products.[30] Onset and duration are generally similar to dried mushroom consumption (30–60 minutes onset, 4–8 hours duration). The primary safety concern is unreliable dosing — users cannot verify psilocybin content without analytical testing.
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
Laboratory testing is the only reliable method to confirm psilocybin content and rule out adulterants. For whole dried mushrooms, visual identification by an experienced mycologist combined with spore-print verification provides reasonable confidence in species identity. Commercial edible products (chocolates, gummies) cannot be visually assessed for content or purity; analytical testing is the only safeguard against inconsistent dosing and synthetic adulterants.[30]
Ehrlich reagent provides a useful but limited screening tool: a purple/violet reaction confirms the presence of an indole tryptamine but cannot distinguish psilocybin from other tryptamine compounds or determine dose. For high-potency cultivars or unfamiliar specimens, starting with a fraction of a typical dose is the most practical harm-reduction strategy in the absence of analytical data.
Guidelines
Practical Guidelines
- 1. Test first. Use Ehrlich reagent at minimum. Purple/violet confirms indole presence. No reaction: do not consume.
- 2. Start low. For unfamiliar specimens or cultivars, begin with 0.5–1 g dried and assess potency before taking more. Specimen-to-specimen variability is substantial.[9]
- 3. Wait before redosing. Onset from dried mushroom material is 30–60 minutes. Do not redose during this window. Tea and lemon tek onset faster (15–30 minutes).
- 4. Prepare your environment. Comfortable indoor space with soft lighting, access to water, calming music, and a sober companion.
- 5. Clear your schedule. Allow 6–8 hours for the experience plus rest time afterward. Do not drive, operate machinery, or make consequential decisions until fully baseline.
- 6. Hydrate and eat lightly. A light meal 2–3 hours before consumption reduces nausea. Keep water accessible throughout.
- 7. Avoid dangerous combinations. Do not combine with lithium, MAOIs, or tramadol.[12]
Set & Setting
Psilocybin's effects are unusually sensitive to psychological state and physical environment. A calm, familiar, physically safe space with minimal external stimulation reduces the likelihood of a challenging experience. Avoid public settings, crowds, or situations requiring coordination or rapid decision-making.
Prepare mentally before consumption. Unresolved anxiety, acute grief, or emotional distress elevates risk for difficult experiences.[27] A trusted, sober companion ("trip sitter") who can provide calm reassurance is strongly recommended, especially for higher doses or first experiences.
Aftercare & integration. The period following a psilocybin experience often carries emotional residue — positive or challenging — that benefits from deliberate processing. Rest, adequate sleep, and good nutrition in the 24–48 hours afterward support recovery.
Journaling or conversation with a trusted person helps consolidate insights and process difficult material. For experiences that included challenging psychological content, integration work is particularly important: unprocessed difficult experiences can manifest as lingering anxiety or confusion.
Mild headache is common in the hours afterward. Hydration and over-the-counter analgesics are typically sufficient. If persistent mood disturbance, depersonalization, or perceptual changes continue beyond a few days, consult a mental health professional.
Recovery & Support
Psilocybin carries very low abuse liability, and most users do not develop problematic patterns. However, some individuals experience psychological difficulty integrating intense psychedelic experiences, or develop habitual use that interferes with daily functioning.
For persistent psychological difficulties after psychedelic use — including anxiety, depersonalization, or existential distress — specialized integration therapy is available through directories such as the Psychedelic Support Network and MAPS therapist finder.
Tolerance resets fully in approximately 7 days. Spacing sessions at least 1–2 weeks apart preserves sensitivity and reduces risk of psychological overload.
For crisis support, contact the Fireside Project psychedelic peer support line (62-FIRESIDE / 623-473-7433) or the SAMHSA National Helpline (1-800-662-4357), available 24/7.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Severe panic or paranoia unresponsive to reassurance
- Dissociation so profound the person cannot communicate or recognize surroundings
- Seizure activity (especially if lithium has been co-administered)
- Signs of serotonin syndrome: hyperthermia, rigid muscles, rapid heart rate, agitation
- Chest pain or difficulty breathing
Immediate steps:
- 1. Stay with the person. Move to a quiet, safe space if possible.
- 2. Speak calmly and reassuringly. Remind them the effects are temporary and will pass.
- 3. If severely distressed and unresponsive to reassurance, call emergency services.
- 4. If seizures occur, protect the head and call emergency services immediately.
What to tell the dispatcher:
- The substance consumed (psilocybin mushrooms), approximate amount, and time of ingestion
- Current symptoms
- Any co-administered substances, particularly lithium or MAOIs
- Good Samaritan laws provide legal protection in many jurisdictions
Reversal agents: No specific pharmacological reversal agent exists for psilocybin. Benzodiazepines may be administered by medical professionals for severe anxiety or agitation.
Legal Status[edit]
Psilocybin and psilocin are listed in Schedule I of the 1971 UN Convention on Psychotropic Substances, though the physical mushroom was not explicitly named — a legal ambiguity exploited in several jurisdictions.[17] The legal landscape is evolving rapidly: Australia authorized therapeutic use in 2023, Oregon and Colorado have established regulated access frameworks, and several European nations have initiated medical-access programmes. Possession remains a serious criminal offense in most jurisdictions worldwide. All status information should be independently verified against current legislation.[7]
| Jurisdiction | Status | Notes |
|---|---|---|
| United States (federal) | Schedule I | Psilocybin and psilocin scheduled under the Controlled Substances Act (1970). An April 2026 executive order directed FDA/DEA to fast-track psychedelic research review — this does not alter Schedule I status[7] |
| Oregon (US) | Regulated therapeutic access | Measure 109 (2020) established licensed psilocybin service centers with trained facilitators; operational since 2023[7] |
| Colorado (US) | Decriminalized; regulated access | Proposition 122 (2022) decriminalized personal possession/cultivation and established the Natural Medicine Health Act framework |
| US cities | Decriminalized (various) | Denver (2019), Oakland, Santa Cruz, Ann Arbor, Washington DC, and Seattle have enacted decriminalization ordinances. citation needed |
| Canada | Schedule III | Special Access Program permits access for serious conditions. In June 2025, Federal Court of Appeal ruled Health Canada's denial of practitioner exemptions was "excessively arbitrary"[7] |
| Australia | Authorized therapeutic medicine (2023) | First country to authorize government-sanctioned therapeutic use, for treatment-resistant depression under licensed psychiatrist supervision[7] |
| United Kingdom | Class A | Schedule 1 Home Office license required for research. Possession is a criminal offense[7] |
| Netherlands | Mushrooms prohibited; truffles legal | Psilocybin-containing fruiting bodies prohibited; truffles (sclerotia) remain legal and sold in licensed smart shops[7] |
| Czech Republic | Medical use framework (January 2026) | First EU member state with a specific legal framework for medical psilocybin[7] |
| Germany | Compassionate access (2025) | EU's first psilocybin compassionate access programme at two clinics[7] |
Treaty and analog considerations
The 1971 Convention schedules psilocybin and psilocin as chemical compounds but does not schedule the organisms that produce them. This distinction has practical legal consequences: in the Netherlands, psilocybin-containing truffles are sold legally because the prohibition specifies fruiting bodies rather than all psilocybin-containing fungi. Similar ambiguities exist in jurisdictions where legislation references the compound rather than the organism.[17]
Frequently asked questions
What is Psilocybin mushrooms?
Psilocybin mushrooms are psychoactive fungi of the genus Psilocybe containing the tryptamine prodrug psilocybin, a serotonergic psychedelic. The active metabolite psilocin acts as a 5-HT2A partial agonist; clinical research since 2006 has investigated therapeutic applications in depression and substance use disorders.
What are dangerous combinations with Psilocybin mushrooms?
The highest-severity documented interactions for Psilocybin mushrooms: MAOIs (Lethal), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Psilocybin mushrooms addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Psilocybin mushrooms: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with LSD, mescaline, DMT, other serotonergic hallucinogens. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abMadsen MK, Fisher PM, Burmester D, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels — Neuropsychopharmacology doi:10.1038/s41386-019-0324-9
- [3]
- [4] ^abGoodwin GM, Aaronson ST, Alvarez O, et al. (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression — New England Journal of Medicine doi:10.1056/nejmoa2206443
- [5]
- [6] ^abcMeshkat S, Malik G, Zeifman RJ, et al. (2025) Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review — Neuroscience and Biobehavioral Reviews doi:10.1016/j.neubiorev.2025.106163
references
- [1]
- [2] ^abMadsen MK, Fisher PM, Burmester D, et al. (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels — Neuropsychopharmacology doi:10.1038/s41386-019-0324-9
- [3]
- [4] ^abGoodwin GM, Aaronson ST, Alvarez O, et al. (2022) Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression — New England Journal of Medicine doi:10.1056/nejmoa2206443
- [5]
- [6] ^abMeshkat S, Malik G, Zeifman RJ, et al. (2025) Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review — Neuroscience and Biobehavioral Reviews doi:10.1016/j.neubiorev.2025.106163